JCJúlia Vieira Carvalho

Júlia Vieira Carvalho

*This is an algorithmically generated author record based on publicly available information.

Júlia Vieira Carvalho has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differential TLR2- and TLR4-Associated Oxidative Responses After Bariatric Surgery: A Cross-Sectional Study in Women

    by Regiane Penaforte Santos, Júlia Vieira Carvalho, Amanda Medeiros Frota Cruz, Luciana Ferreira Antunes, Juliana Silveira Gontijo Rigueira, Cláudia Maria Andrade Fernandes Vieira, Edmarcio Olinto da Fonseca, Caroline Maria de Oliveira Volpe

    Background/Objectives: Obesity is characterized by chronic low-grade inflammation and oxidative stress, mediated in part by Toll-like receptor (TLR)-associated pathways. Bariatric surgery improves clinical and metabolic parameters, but its effects on TLR-associated reactive oxygen species (ROS) responses in immune cells remain unclear. This study aimed to investigate ROS production following TLR2- and TLR4-associated stimulation in granulocytes from women with obesity before and after bariatric surgery, compared with age-matched non-obese controls. Methods: ROS production was evaluated using a luminol-dependent chemiluminescence assay in granulocytes isolated from women with obesity before (PRE, n = 12) and after (POST, n = 12) bariatric surgery, as well as from age-matched non-obese controls (n = 12). ROS production was assessed under basal conditions and following stimulation with lipopolysaccharide (LPS, a TLR4 agonist) or zymosan (ZY, a TLR2-associated stimulus). Clinical, anthropometric, and biochemical parameters were assessed, and their associations with ROS production were analyzed. Results: Bariatric surgery was associated with significant improvements in clinical and metabolic parameters, although mean BMI in the POST group remained within the obesity range. Granulocytes from the PRE group exhibited increased basal ROS production and enhanced responses following both LPS and ZY stimulation. In the POST group, basal ROS production and the response following ZY stimulation were comparable to those observed in controls, whereas LPS-associated ROS production remained elevated. Correlation analyses showed positive associations between anthropometric and biochemical parameters and ROS production in both PRE and POST groups, with body weight and BMI remaining positively associated with basal and LPS-associated ROS production after surgery. Conclusions: Bariatric surgery was associated with substantial clinical and metabolic improvement but did not completely restore innate immune redox homeostasis. The persistence of TLR4-driven ROS production suggests that some alterations in innate immune redox balance may persist after surgery despite metabolic improvement.

  • Open Access

    Edaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients

    by Luciana Ferreira Antunes, Regiane Penaforte Santos, Júlia Vieira Carvalho, Paulo Pereira Christo, Pedro Henrique Villar-Delfino, Caroline Maria Oliveira Volpe

    Background: Multiple sclerosis (MS) is a neurological disorder that is directly linked to inflammation in the central nervous system (CNS). The activation of toll-like receptors (TLRs) exacerbates neuroinflammation by increasing the production of reactive oxygen species (ROS) and proinflammatory cytokines. Edaravone (EDV) has been proposed as a potential therapy for CNS diseases because of its free radical scavenging and anti-inflammatory properties. This study investigated the effects of EDV on the inflammatory response in TLR4-stimulated peripheral blood mononuclear cells (PBMNCs) from MS patients and a healthy control group. Methods: The impact of EDV on ROS production in lipopolysaccharide (LPS)-stimulated PBMNCs was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reduction and luminol-dependent chemiluminescence assays. The interleukin (IL)-6 concentration in the PBMNC supernatants was measured using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that ROS production in PBMNCs stimulated using LPS (a TLR4 activator) was significantly inhibited (p < 0.05) by EDV in the MS patients and control group. Additionally, EDV significantly reduced IL-6 secretion in TLR4-stimulated PBMNCs in these groups (p < 0.05). No significant differences were observed between the groups. Conclusion: Our findings suggest that EDV may serve as an adjunctive therapy for MS by reducing ROS and IL-6 production in TLR4-stimulated PBMNCs in MS patients, highlighting its potential in modulating neuroinflammation and oxidative stress.